Minister of Industry Visits Amoun Pharmaceuticals Plant in Obour,
Edit: maher badr
Commends Its Role in Supporting Drug Security and Expanding Egyptian Pharmaceutical Exports.
Investments close to EGP 9 billion, annual production capacity of 333 million packs, and exports reaching EGP 850 million in 2025.
As part of his field visits to review operations at industrial facilities and support the state’s efforts to enhance the competitiveness of national industry, Eng. Khaled Hashem, Minister of Industry, accompanied by Dr. Hossam Abdel Fattah, Governor of Qalyubia, visited the Amoun Pharmaceuticals plant in Obour Industrial City. The plant is one of the companies operating under Arcera Global Life Sciences. The visit aimed to review the different stages of production and learn more about the plant’s capabilities and its contribution to Egypt’s pharmaceutical manufacturing sector.
During the visit, company officials outlined the plant’s key strengths and capabilities. The facility covers more than 58,000 square meters, with total investments approaching EGP 9 billion. Its annual production capacity stands at around 333 million packs, while the local content ratio is approximately 30%. The plant also creates nearly 2,700 direct and indirect job opportunities, highlighting its important industrial and economic role in supporting the local market and contributing to employment generation.
The company also presented its export performance, noting that exports from the Amoun plant reached approximately EGP 850 million in 2025. This reflects the company’s strategy to expand its footprint in international markets and reinforce the presence of Egyptian pharmaceuticals across a number of regional and global markets, in support of the state’s efforts to increase exports and enhance the competitiveness of Egyptian products.
During the tour, the Minister inspected several production lines at the plant, including lines dedicated to liquid formulations, effervescent products, and tablets. He also reviewed the quality system in place, which is based on strict inspection and control procedures designed to ensure the quality and safety of pharmaceutical products in line with internationally recognized manufacturing standards.
The Minister praised the plant’s advanced technological capabilities, emphasizing that the pharmaceutical industry is one of the strategic sectors receiving strong state support, given its vital role in strengthening drug security and providing citizens with high-quality medicines. He also underlined the sector’s significant potential to grow exports and increase the presence of Egyptian industry in international markets.
Dr. Mohamed Heshmat, Chairman of Amoun Pharmaceuticals and Head of Arcera Egypt Region (Amoun and Acino), reaffirmed the company’s commitment to applying the highest quality standards approved by the Egyptian Drug Authority. He noted that Amoun continues to upgrade its production and technological capabilities on an ongoing basis, in line with the state’s direction toward strengthening drug security and increasing exports, as part of its active contribution to the goals of Egypt Vision 2030.
Amoun, one of Arcera’s companies, is part of Arcera Life Sciences and is one of Egypt’s leading manufacturers and exporters of branded pharmaceuticals.
Arcera brings together Amoun and Acino. Arcera in Egypt has launched a strategic realignment (copromotion) between Amoun and Acino, enabling greater focus on therapy areas and expanding options for better patient care while ensuring sustainable quality supply.
